Literature DB >> 15166451

Cell surface activation of the alternative complement pathway by the fusion protein of measles virus.

Patricia Devaux1, Dale Christiansen1, Sébastien Plumet1, Denis Gerlier1.   

Abstract

Measles virus (MV)-infected cells are activators of the alternative human complement pathway, resulting in high deposition of C3b on the cell surface. Activation was observed independent of whether CD46 was used as a cellular receptor and did not correlate with CD46 down-regulation. The virus itself was an activator of the alternative pathway and was covered by C3b/C3bi, resulting in some loss in infectivity without loss of virus binding to target cells. The cell surface expression of MV fusion (F), but not haemagglutinin, envelope protein resulted in complement activation of the Factor B-dependent alternative pathway in a dose-dependent manner and F-C3b complexes were formed. The underlying activation mechanism was not related to any decrease in cell surface expression of the complement regulators CD46 and CD55. The C3b/C3bi coating of MV-infected cells and virus should ensure enhanced targeting of MV antigens to the immune system, through binding to complement receptors.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15166451     DOI: 10.1099/vir.0.79880-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  14 in total

1.  Immunoglobulin g antibody-mediated enhancement of measles virus infection can bypass the protective antiviral immune response.

Authors:  Ianko D Iankov; Manoj Pandey; Mary Harvey; Guy E Griesmann; Mark J Federspiel; Stephen J Russell
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

Review 2.  Paramyxovirus activation and inhibition of innate immune responses.

Authors:  Griffith D Parks; Martha A Alexander-Miller
Journal:  J Mol Biol       Date:  2013-09-20       Impact factor: 5.469

3.  Virion-associated complement regulator CD55 is more potent than CD46 in mediating resistance of mumps virus and vesicular stomatitis virus to neutralization.

Authors:  John B Johnson; Douglas S Lyles; Martha A Alexander-Miller; Griffith D Parks
Journal:  J Virol       Date:  2012-07-03       Impact factor: 5.103

4.  Dendritic cells and T cells deliver oncolytic reovirus for tumour killing despite pre-existing anti-viral immunity.

Authors:  E J Ilett; R J Prestwich; T Kottke; F Errington; J M Thompson; K J Harrington; H S Pandha; M Coffey; P J Selby; R G Vile; A A Melcher
Journal:  Gene Ther       Date:  2009-03-12       Impact factor: 5.250

5.  The paramyxoviruses simian virus 5 and mumps virus recruit host cell CD46 to evade complement-mediated neutralization.

Authors:  John B Johnson; Ken Grant; Griffith D Parks
Journal:  J Virol       Date:  2009-05-20       Impact factor: 5.103

6.  Differential mechanisms of complement-mediated neutralization of the closely related paramyxoviruses simian virus 5 and mumps virus.

Authors:  John B Johnson; Gerald A Capraro; Griffith D Parks
Journal:  Virology       Date:  2008-04-28       Impact factor: 3.616

Review 7.  Drivers and regulators of humoral innate immune responses to infection and cancer.

Authors:  Deepak Kumar; Yeni Romero; Kaitlynn N Schuck; Haley Smalley; Bibek Subedi; Sherry D Fleming
Journal:  Mol Immunol       Date:  2020-03-18       Impact factor: 4.407

8.  Sequence of events in measles virus replication: role of phosphoprotein-nucleocapsid interactions.

Authors:  Joanna Brunel; Damien Chopy; Marion Dosnon; Louis-Marie Bloyet; Patricia Devaux; Erica Urzua; Roberto Cattaneo; Sonia Longhi; Denis Gerlier
Journal:  J Virol       Date:  2014-07-09       Impact factor: 5.103

9.  Point mutations in the paramyxovirus F protein that enhance fusion activity shift the mechanism of complement-mediated virus neutralization.

Authors:  John B Johnson; Anthony P Schmitt; Griffith D Parks
Journal:  J Virol       Date:  2013-06-19       Impact factor: 5.103

10.  Protective immune responses against West Nile virus are primed by distinct complement activation pathways.

Authors:  Erin Mehlhop; Michael S Diamond
Journal:  J Exp Med       Date:  2006-05-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.